New therapies for chronic obstructive pulmonary disease.
Krishna G, Sankaranarayanan V, & Chitkara RK.
Expert Opin Investig Drugs. 13(3):255-67.
2004-03-01
Abstract
Chronic obstructive pulmonary disease (COPD) is the most common lung disease, carrying a significant mortality and morbidity. None of the therapeutic interventions currently available alter the progression of the disease.
As our understanding of the basic mechanisms of alveolar destruction and airflow limitation improves, new targets are identified that may eventually result in treatment options which will affect the progression of this disease.
In this review, we discuss some of the novel therapeutic options recently developed that may have an impact on the management of COPD.
Future directions in research and development of pharmacological agents based on improved understanding of COPD are also discussed.
Research topics
Related publications
View all publications- Katikireddy CK, Krishna G, Keifer T, Kuschner W, Rosen G.Chest. 129(2):482-7.2006 Feb 01
- Sciurba FC, Criner GJ, Strange C, Shah PL, Michaud G, Connolly TA, Deslée G, Tillis WP, Delage A, Marquette CH, Krishna G, Kalhan R, Ferguson JS, Jantz M, Maldonado F, McKenna R, Majid A, Rai N, Gay S, Dransfield MT, Angel L, Maxfield R, Herth FJ, Wahidi MM, Mehta A, Slebos DJ; RENEW Study Research Group.JAMA. 315(20):2178-2189. doi: 10.1001/jama.2016.6261.2016 May 24
- Katikireddy CK, Krishna G, Berry G, Faul J, Kuschner W.Chest. 128(6):4013-7.2005 Dec 01
- Publication
The dying thoracic patient.
Krishna G, Raffin TA.Chest Surg Clin N Am. 8(3):723-39.1998 Aug 01 - Meinke L, Chitkara R, Krishna G.Expert Opin Pharmacother. 8(1):23-37.2007 Jan 01